BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 18836086)

  • 1. Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and follow-up in 16 patients.
    Valencak J; Weihsengruber F; Rappersberger K; Trautinger F; Chott A; Streubel B; Muellauer L; Der-Petrossian M; Jonak C; Binder M; Raderer M
    Ann Oncol; 2009 Feb; 20(2):326-30. PubMed ID: 18836086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
    Gellrich S; Muche JM; Wilks A; Jasch KC; Voit C; Fischer T; Audring H; Sterry W
    Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete remission of a primary cutaneous B-cell lymphoma of the lower leg by first-line monotherapy with the CD20-antibody rituximab.
    Bonnekoh B; Schulz M; Franke I; Gollnick H
    J Cancer Res Clin Oncol; 2002 Mar; 128(3):161-6. PubMed ID: 11935303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Anti-CD20 antibodies in primary cutaneous B-cell lymphoma. Initial results in dermatologic patients].
    Gellrich S; Muche JM; Pelzer K; Audring H; Sterry W
    Hautarzt; 2001 Mar; 52(3):205-10. PubMed ID: 11284065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic therapy with cyclophosphamide and anti-CD20 antibody (rituximab) in relapsed primary cutaneous B-cell lymphoma: a report of 7 cases.
    Fierro MT; Savoia P; Quaglino P; Novelli M; Barberis M; Bernengo MG
    J Am Acad Dermatol; 2003 Aug; 49(2):281-7. PubMed ID: 12894078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases.
    Kerl K; Prins C; Saurat JH; French LE
    Br J Dermatol; 2006 Dec; 155(6):1197-200. PubMed ID: 17107389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of primary cutaneous follicular centre lymphoma with rituximab: a report of two cases.
    Kennedy GA; Blum R; McCormack C; Prince HM
    Australas J Dermatol; 2004 Feb; 45(1):34-7. PubMed ID: 14961906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab plus liposomal pegylated doxorubicin in the treatment of primary cutaneous B-cell lymphomas.
    Fabbri A; Cencini E; Alterini R; Rubegni P; Rigacci L; Delfino C; Puccini B; Fimiani M; Bosi A; Bocchia M; Pimpinelli N;
    Eur J Haematol; 2014 Aug; 93(2):129-36. PubMed ID: 24635751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous B-cell lymphoma responds to rituximab: a report of five cases and a review of the literature.
    Gitelson E; Al-Saleem T; Millenson M; Lessin S; Smith MR
    Leuk Lymphoma; 2006 Sep; 47(9):1902-7. PubMed ID: 17065004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term Therapeutic Success of Intravenous Rituximab in 26 Patients with Indolent Primary Cutaneous B-cell Lymphoma.
    Porkert S; Mai P; Jonak C; Weihsengruber F; Rappersberger K; Bauer W; Simonitsch-Klupp I; Raderer M; Valencak J
    Acta Derm Venereol; 2021 Feb; 101(2):adv00383. PubMed ID: 33475146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma.
    Raderer M; Jäger G; Brugger S; Püspök A; Fiebiger W; Drach J; Wotherspoon A; Chott A
    Oncology; 2003; 65(4):306-10. PubMed ID: 14707449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcome of intravenous therapy with rituximab in patients with primary cutaneous B-cell lymphomas.
    Brandenburg A; Humme D; Terhorst D; Gellrich S; Sterry W; Beyer M
    Br J Dermatol; 2013 Nov; 169(5):1126-32. PubMed ID: 23796422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab.
    Morales AV; Advani R; Horwitz SM; Riaz N; Reddy S; Hoppe RT; Kim YH
    J Am Acad Dermatol; 2008 Dec; 59(6):953-7. PubMed ID: 18817999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study.
    Jermann M; Jost LM; Taverna Ch; Jacky E; Honegger HP; Betticher DC; Egli F; Kroner T; Stahel RA
    Ann Oncol; 2004 Mar; 15(3):511-6. PubMed ID: 14998858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary cutaneous marginal zone B-cell lymphoma: response to treatment and disease-free survival in a series of 137 patients.
    Servitje O; Muniesa C; Benavente Y; Monsálvez V; Garcia-Muret MP; Gallardo F; Domingo-Domenech E; Lucas A; Climent F; Rodriguez-Peralto JL; Ortiz-Romero PL; Sandoval J; Pujol RM; Estrach MT
    J Am Acad Dermatol; 2013 Sep; 69(3):357-65. PubMed ID: 23796549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intralesional anti-CD20 antibody for low-grade primary cutaneous B-cell lymphoma: Adverse reactions correlate with favorable clinical outcome.
    Eberle FC; Holstein J; Scheu A; Fend F; Yazdi AS
    J Dtsch Dermatol Ges; 2017 Mar; 15(3):319-323. PubMed ID: 28177583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab monotherapy is highly effective in splenic marginal zone lymphoma.
    Kalpadakis C; Pangalis GA; Dimopoulou MN; Vassilakopoulos TP; Kyrtsonis MC; Korkolopoulou P; Kontopidou FN; Siakantaris MP; Dimitriadou EM; Kokoris SI; Tsaftaridis P; Plata E; Angelopoulou MK
    Hematol Oncol; 2007 Sep; 25(3):127-31. PubMed ID: 17514771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cutaneous B-cell lymphoma treatment with rituximab: two cases].
    Viguier M; Bachelez H; Brice P; Rivet J; Dubertret L
    Ann Dermatol Venereol; 2002 Oct; 129(10 Pt 1):1152-5. PubMed ID: 12442128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeat treatment with iodine-131-rituximab is safe and effective in patients with relapsed indolent B-cell non-Hodgkin's lymphoma who had previously responded to iodine-131-rituximab.
    Bishton MJ; Leahy MF; Hicks RJ; Turner JH; McQuillan AD; Seymour JF
    Ann Oncol; 2008 Sep; 19(9):1629-33. PubMed ID: 18522934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic therapy of primary cutaneous B-cell lymphoma, marginal zone type, with rituximab, a chimeric anti-CD20 monoclonal antibody.
    Soda R; Costanzo A; Cantonetti M; Orlandi A; Bianchi L; Chimenti S
    Acta Derm Venereol; 2001; 81(3):207-8. PubMed ID: 11558880
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.